Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news


First-timer resumes PBAC fight

Posted 22 February 2021 PM

After registering its first product in Australia this month, Kyowa Kirin has confirmed it will continue to pursue reimbursement for Poteligeo despite already being rejected twice by the PBAC.

Prior to the TGA's approval, the medicine had been knocked back at the PBAC's July meeting and November meeting in 2020 for two rare forms of lymphoma - mycosis fungoides and Sezary syndrome.

Looks like you've lost your access to Pharma in Focus. To restore access or update your subscription, click here

Approvals Action
Pfizer vs Humira
Adds to a growing list of adalimumab biosims
Top of the Hill
How not to reform the PBAC
In the face of deep change, is piecemeal enough?
Special Report
Aust Covid Vaccine Tracker
UPDATE: Distribution of two mRNA vaccines overseas